Glycodeoxycholic Acid-d4 (Synonyms: GDCA-d4) |
| Catalog No.GC47411 |
A quantitative analytical standard guaranteed to meet MaxSpec® identity, purity, stability, and concentration specifications
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1069132-37-1
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Glycodeoxycholic acid-d4 is intended for use as an internal standard for the quantification of glycodeoxycholic acid by GC- or LC-MS. Glycodeoxycholic acid (GDCA) is a glycine-conjugated form of the secondary bile acid deoxycholic acid .1 It induces a reversible, concentration-dependent reduction in myogenic tone in rats and decreases expression of the gene encoding the cytochrome P450 (CYP) isoform 7A1 (CYP7A1) in rabbits.2,3 Serum levels of GDCA are elevated in non-surviving patients with acetaminophen-induced acute liver failure (AALF) compared with survivors.4 GDCA levels are also increased in the plasma of patients with asthma.5
1.Lefebvre, P., Cariou, B., Lien, F., et al.Role of bile acids and bile acid receptors in metabolic regulationPhysiol. Rev.89(1)147-191(2009) 2.Khurana, S., Raina, H., Pappas, V., et al.Effects of deoxycholylglycine, a conjugated secondary bile acid, on myogenic tone and agonist-induced contraction in rat resistance arteriesPLoS One7(2)e32006(2012) 3.Shang, Q., Guo, G.L., Honda, A., et al.Bile acid flux through portal but not peripheral veins inhibits CYP7A1 expression without involvement of ileal FGF19 in rabbitsAm. J. Physiol. Gastrointest. Liver Physiol.307(4)G479-G486(2014) 4.Woolbright, B.L., McGill, M.R., Staggs, V.S., et al.Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patientsToxicol. Sci.142(2)436-444(2014) 5.Comhair, S.A.A., McDunn, J., Bennett, C., et al.Metabolomic endotype of asthmaJ. Immunol.195(2)643-650(2015)
| Cas No. | 1069132-37-1 | SDF | |
| Synonyms | GDCA-d4 | ||
| Canonical SMILES | C[C@H](CCC(NCC(O)=O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C([2H])([2H])[C@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C | ||
| Formula | C26H39D4NO5 | M.Wt | 453.7 |
| Solubility | DMSO : 125 mg/mL (275.54 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2041 mL | 11.0205 mL | 22.041 mL |
| 5 mM | 0.4408 mL | 2.2041 mL | 4.4082 mL |
| 10 mM | 0.2204 mL | 1.102 mL | 2.2041 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *